MedinCell (MEDCL) R&D Day 2026 summary

Pipeline overview and program updates

• UZEDY, a risperidone LAI, is demonstrating strong adoption in a competitive market, validating the platform approach.

• Olanzapine LAI is awaiting regulatory approval, with a differentiated safety profile and significant market potential.

• The pipeline includes both internal and external programs, with a focus on schizophrenia and expansion into other therapeutic areas.

• Six LAI programs are prioritized under the AbbVie collaboration, with the first expected to enter clinical studies soon.

Clinical trial data and development milestones

• UZEDY's clinical data show immediate onset of action and improved patient/physician adoption due to ease of use.

• Olanzapine LAI demonstrated no PDSS events in ~4,000 injections, addressing prior safety concerns.

• BEPO Star platform may enter clinical trials in 2028, with commercial launch targeted for 2033.

R&D strategy and innovation priorities

• R&D is focused on platform expansion, risk reduction, and accelerating development through automation and data-driven approaches.

• Platform innovation includes BEPO, BEPO Star, and next-gen technologies, each expanding formulation capabilities and adoption.

• Complementary innovation targets API optimization, delivery devices, and external technology scouting.